Drug intelligence / Profile preview

C-271

Development stage: Preclinical
Lead developer: Cytosinlab Pharmaceutical Technology
Modality: Small Molecules

Overview

C-271 is a preclinical small molecule inhibitor of Thymine DNA Glycosylase (TDG), currently under development by Cytosinlab Pharmaceutical Technology. TDG is a key enzyme in the base excision repair (BER) pathway, responsible for removing thymine and uracil from G/T and G/U mismatches, and it plays a crucial role in epigenetic regulation through the demethylation of 5-methylcytosine. By inhibiting TDG, C-271 aims to disrupt DNA repair mechanisms and alter the epigenetic landscape of cancer cells, potentially leading to genomic instability or synthetic lethality in specific tumor types. The drug is being investigated for its potential therapeutic application in various neoplasms.

Targets

DDR (DNA damage response)

Beyond the preview

Go deeper on C-271.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on C-271.

Explore the full profile